Published in PLoS One on December 15, 2014
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Front Oncol (2015) 0.87
Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme. PLoS One (2016) 0.83
In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma. J R Soc Interface (2015) 0.75
Fast and high temperature hyperthermia coupled with radiotherapy as a possible new treatment for glioblastoma. J Ther Ultrasound (2016) 0.75
Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary. PLoS One (2017) 0.75
The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) (2017) 0.75
Key rates for the grades and transformation ability of glioma: model simulations and clinical cases. J Neurooncol (2017) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Angiogenic factors. Science (1987) 15.22
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol (2008) 2.97
MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol (2005) 2.70
Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One (2011) 2.35
Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg (1987) 2.32
Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol (1996) 2.04
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med (1989) 1.85
Computer simulation of glioma growth and morphology. Neuroimage (2007) 1.83
A cellular automaton model for tumour growth in inhomogeneous environment. J Theor Biol (2003) 1.81
Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res (2011) 1.72
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest (1996) 1.63
Image guided personalization of reaction-diffusion type tumor growth models using modified anisotropic eikonal equations. IEEE Trans Med Imaging (2009) 1.31
'Go or grow': the key to the emergence of invasion in tumour progression? Math Med Biol (2010) 1.27
MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A (2014) 1.25
Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia (2014) 1.23
Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol (2009) 1.17
Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol (2013) 1.11
Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell (2004) 1.10
The "go or grow" potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol (2012) 1.10
Extrapolating glioma invasion margin in brain magnetic resonance images: suggesting new irradiation margins. Med Image Anal (2009) 0.98
The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS One (2012) 0.94
Pros and cons of current brain tumor imaging. Neuro Oncol (2014) 0.92
Hypoxia-induced tumour cell migration in an in vivo chicken model. Pathobiology (2001) 0.88
Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI. J Neurooncol (2014) 0.87
c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas. PLoS One (2013) 0.83
A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth. Bull Math Biol (2014) 0.82
Bevacizumab for glioblastoma: what can we learn from patterns of progression? Neurology (2014) 0.79
Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme. J Neurooncol (2013) 0.78